- Home
- OBDC vs VRNA Comparison
OBDC vs VRNA Comparison
Compare OBDC & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBDC
- VRNA
- Stock Information
- Founded
- OBDC 2015
- VRNA 2005
- Country
- OBDC United States
- VRNA United Kingdom
- Employees
- OBDC N/A
- VRNA N/A
- Industry
- OBDC Investment Managers
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- OBDC Finance
- VRNA Health Care
- Exchange
- OBDC Nasdaq
- VRNA Nasdaq
- Market Cap
- OBDC 7.5B
- VRNA 7.8B
- IPO Year
- OBDC 2019
- VRNA 2017
- Fundamental
- Price
- OBDC $14.47
- VRNA $92.20
- Analyst Decision
- OBDC Buy
- VRNA Strong Buy
- Analyst Count
- OBDC 8
- VRNA 7
- Target Price
- OBDC $15.50
- VRNA $97.57
- AVG Volume (30 Days)
- OBDC 2.1M
- VRNA 1.4M
- Earning Date
- OBDC 08-06-2025
- VRNA 08-07-2025
- Dividend Yield
- OBDC 11.40%
- VRNA N/A
- EPS Growth
- OBDC N/A
- VRNA N/A
- EPS
- OBDC 1.57
- VRNA N/A
- Revenue
- OBDC $1,661,827,000.00
- VRNA $118,535,000.00
- Revenue This Year
- OBDC $20.49
- VRNA $891.79
- Revenue Next Year
- OBDC N/A
- VRNA $78.94
- P/E Ratio
- OBDC $9.20
- VRNA N/A
- Revenue Growth
- OBDC 3.60
- VRNA N/A
- 52 Week Low
- OBDC $12.11
- VRNA $14.14
- 52 Week High
- OBDC $15.98
- VRNA $94.45
- Technical
- Relative Strength Index (RSI)
- OBDC 48.95
- VRNA 78.05
- Support Level
- OBDC $14.36
- VRNA $82.18
- Resistance Level
- OBDC $14.67
- VRNA $93.74
- Average True Range (ATR)
- OBDC 0.18
- VRNA 3.21
- MACD
- OBDC -0.03
- VRNA 0.89
- Stochastic Oscillator
- OBDC 21.65
- VRNA 92.52
About OBDC Blue Owl Capital Corporation
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.